A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Persistent or Chronic Primary Immune Thrombocytopenia

Around one in five patients with immune thrombocytopenia (ITP) stop responding to existing drugs, leaving them at risk of severe or life-threatening bleeding. ITP is an autoimmune disorder where the body destroys its own platelets, the cells that form clots. This trial tests a new injectable drug, mezagitamab, in a phase 3 randomised, double-blind, placebo-controlled study. The goal is to see whether it can produce a sustained rise in platelet counts, prevent bleeding episodes, and improve quality of life for patients who have already failed or cannot tolerate current therapies. If mezagitamab proves effective and safe, it would offer a new treatment option for a group that currently has few alternatives. That could reduce hospitalisations for bleeding emergencies, lower the need for rescue therapies, and allow patients to live with less fear of a sudden haemorrhage. The trial is a direct test of a practical intervention, not fundamental science—success would mean a new drug entering the clinic for a condition with an unmet medical need.